Clinical trials: Diabetic Kidney Disease
Diabetic Kidney Disease
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
This is a dose ranging study to evaluate the safety and efficacy of baricitinib in the treatment of participants with mild to moderate diabetic kidney disease.
- Trial name
- NCT01683409
- Testing
- Baricitinib
- Where
- 45 sites in United States, Japan and 2 more
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Diabetic Kidney Disease
Renal Mechanism of SGLT2 Inhibition
Canagliflozin is an oral drug which is currently approved for use in patients with type 2 diabetes by the US Food and Drug Administration (FDA).
- Trial name
- NCT05507892
- Testing
- canagliflozin, Aminohippurate Sodium Inj 20%
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Colorado, Denver
Type 1 Diabetes
Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy
A number of arguments suggest that the deterioration in high density lipoproteins (HDL) functioning may worsen with the development of nephropathy during type 1 diabetes (T1D).
- Trial name
- DID&NEPHRO (NCT03512132)
- Testing
- Blood samples, Urine sample
- Where
- France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Diabetic Kidney Disease (DKD)
Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
This phase 2a, double-blind, randomized, placebo-controlled study will assess the efficacy, safety, tolerability, and pharmacokinetics (PK), of repeat doses of CSL346 in subjects with diabetic kidney disease (DKD) and albuminuria…
- Trial name
- NCT04419467
- Testing
- CSL346
- Where
- 37 sites in United States, Australia and 4 more
- Volunteers
- 114 people
- Sponsor
- CSL Behring
Diabetic Nephropathies
Colchicine for Diabetic Nephropathy Trial
Forty patients with diabetic nephropathy will be treated with colchicine up to 2 mg, or placebo, for 18 months. A follow up will be performed after 12 additional months.
- Trial name
- CDNT (NCT02442921)
- Testing
- Colchicine
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Sheba Medical Center
Diabetic Nephropathies
Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis
Diabetic kidney disease (DKD) is a serious complication of diabetes, and it is also the leading cause of end-stage renal disease (ESRD) in the world.
- Trial name
- NCT06031389
- Testing
- Henagliflozin
- Volunteers
- 120 people
- Sponsor
- Qianfoshan Hospital
Diabetes Mellitus, Type 2, Chronic Kidney Disease
Type 2 Diabetes and Associated Factors in Mexico
The goal of this observational cross-sectional multicenter study is to identify clinical, lifestyle, metabolic, inflammatory, and genetic factors associated with glycemic control and complications of Type 2 Diabetes (T2D) in…
- Conditions
- Diabetes Mellitus, Type 2, Chronic Kidney Disease, Diabetic Nephropathy
- Trial name
- NCT07248891
- Testing
- Clinical and Molecular Assessment
- Where
- 3 sites in Mexico
- Volunteers
- 1,000 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Diabetic Nephropathy
Study on the Efficacy and Safety of a Novel Tripterygium Wilfordii Preparation in Reducing Proteinuria in Patients With Diabetic Nephropathy
The investigators designed a randomized parallel controlled clinical study, selected 98 cases of diabetic nephropathy patients with urinary protein > 1g, randomly assigned into the Kunxian capsule + irbesartan group or irbesartan…
- Trial name
- NCT04981613
- Testing
- Kunxian capsule
- Where
- China
- Volunteers
- 80 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Diabetic Nephropathy, Diabetes Mellitus
Soy Protein in Early Diabetic Nephropathy
Diabetic nephropathy is a frequent cause of end-stage renal disease. Reduction of dietary protein has been used to slow down renal disease progression, but patients are often unwilling to make these dietary changes.
- Trial name
- NCT00067678
- Testing
- soy protein
- Where
- United States
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Diabetic Kidney Disease
A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study
The purpose of this study is to demonstrate the efficacy of multiple oral doses of RTA 402 (5, 10, or 15 mg) administered once daily in patients with diabetic kidney disease (DKD) using the time to onset of a ≥ 30% decrease in…
- Trial name
- NCT03550443
- Testing
- Bardoxolone methyl
- Where
- Japan
- Volunteers
- 1,323 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Diabetic Nephropathies
PERL Continuous Glucose Monitoring (CGM) Study
Seven-point capillary profiles have shown that mean glucose correlates with both diabetic retinopathy and nephropathy risk. However, there remains great controversy as to whether the degree of variability around mean glucose may…
- Trial name
- NCT03334318
- Testing
- Mean blood glucose, Blood glucose CV, % time 70-180 mg/dL
- Where
- 19 sites in United States, Canada
- Volunteers
- 175 people
- Sponsor
- Joslin Diabetes Center
Diabetic Nephropathy, Hypertension
Effect of Green Tea (Epigallocatechin Gallate) on Albuminuria in Patients With Diabetic Nephropathy.
The purpose of this study is to determine the safety and effect of green tea (epigallocatechin gallate) in albuminuria in diabetic patients and nephropathy.
- Trial name
- NCT01923597
- Testing
- Green tea extract
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- University of Campinas, Brazil
Diabetic Kidney Disease
Pentoxifylline in Diabetic Kidney Disease
Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs.
- Trial name
- VA PTXRx (NCT03625648)
- Testing
- Pentoxifylline
- Where
- 34 sites in United States
- Volunteers
- 2,376 people
- Sponsor
- VA Office of Research and Development
Kidney Diseases, Diabetic Nephropathies
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
GFB-024 is intended for use in patients with kidney disease such as diabetic nephropathy. This study is the first time GFB-024 has been used in humans.
- Conditions
- Kidney Diseases, Diabetic Nephropathies, Diabetes Complications, Diabetes Mellitus
- Trial name
- NCT04880291
- Testing
- GFB-024
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Goldfinch Bio, Inc.
Diabetic Nephropathy Type 2
Effect of Exercise Therapy on Type II Diabetic Neuropathic Patients
The goal of this Randomized control trial (clinical trial) is to learn about the effect of Exercise therapy on Type II Diabetic Neuropathic Patient in Pakistan ,40-70 year's old patient, will be refer by physicians.
- Trial name
- NCT06332378
- Testing
- Experimental group 1 :Ball training, Experimental group 2 :Frenkel Exercises, Control Group
- Where
- Pakistan
- Volunteers
- 90 people
- Sponsor
- Dr. Sobia Hasan
Diabetic Kidney Disease
Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)
This study will evaluate the efficacy and Safety of QiShen YiQi Dripping Pills in the treatment of Diabetic Kidney Disease (syndrome of Qi deficiency with blood stasis)
- Trial name
- NCT06006689
- Testing
- Low dose Qishen Yiqi Dripping Pills 3 bags, High dose Qishen Yiqi Dripping Pills 3 bags
- Where
- 16 sites in China
- Volunteers
- 228 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Diabetes, Hypertension
Real-world Aliskiren Use in Diabetic Patients
The purpose of this study is to evaluate real-world patterns of aliskiren use with a focus of change in renal function following aliskiren initiation as well as to identify "triggering events" that lead to aliskiren initiation.
- Trial name
- NCT01393860
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Novartis
Diabetes, End Stage Renal Disease
Continuous Glucose Monitoring and Inflammation in Nondiabetic and Diabetic Patients Undergone Hemodialysis
Evaluation of different glycemic variations between the dialysis period and non-dialysis period in two groups: nondiabetic and diabetic patients undergone two different hemodialysis methods.
- Trial name
- NCT01049152
- Testing
- Continuous Glucose Monitoring (CGM)
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- University of Pavia
Diabetic Chronic Kidney Disease Patients
Impact of Diabetes-Related Metabolic Derangements on Clinical Outcomes in Hospitalized Patients With Chronic Kidney Disease
This observational study will collect clinical and laboratory information from hospitalized patients with chronic kidney disease to identify diabetes mellitus and selected metabolic findings during hospitalization
- Trial name
- NCT07354958
- Testing
- Primary aim 1. To assess the frequency of diabetes mellitus among hospitalized CKD patients. 2. To evaluate the frequency and types of metabolic abnormalities (e.g., hypoglycemia, diabetic ketoacidosi
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Sohag University
Type2 Diabetes Mellitus
Heart Rate Variability and Diabetic Kidney Disease in Type 2 Diabetes Mellitus Patients
Several studies have investigated an association between cardiac autonomic neuropathy (CAN) and albuminuria, glomerular filtration rate, or both, and hypothesized that CAN is involved in the pathogenesis of nephropathy.
- Trial name
- NCT02996539
- Testing
- Clinical examination and laboratory measurements
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Shi wei, MM